Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, U.S. Commercial | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 63,647 |
Reported balance
After 2026-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-30 · Sale · Disposed 21,258 · Balance 63,647 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 4, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 21,258 | $35.31 | $750,619.98 |
DisclosureSEC source: 0001193125-26-203920 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,647 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.28 to $35.33, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098541 · ownership.xml · derivative · entry 3 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,459 Underlying: Ordinary Shares · 17,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,924 | $31.67 | $250,940.40 |
DisclosureSEC source: 0001193125-26-098541 · ownership.xml · nonDerivative · entry 2 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,905 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098541 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 50,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096498 · ownership.xml · derivative · entry 4 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,643 Underlying: Ordinary Shares · 50,643 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096498 · ownership.xml · derivative · entry 3 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,923 Underlying: Ordinary Shares · 20,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,098 | $32.46 | $295,362.02 |
DisclosureSEC source: 0001193125-26-096498 · ownership.xml · nonDerivative · entry 2 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,010 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096498 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 63,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-293655 · ownership.xml · derivative · entry 3 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,984 Underlying: Ordinary Shares · 63,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on November 20, 2023, with 63,492 vested on each of November 20, 2024 and November 20, 2025, and 63,492 vesting on each of November 20, 2026 and November 20, 2027. F5 · derivative.expiration_date: Restricted share units were granted on November 20, 2023, with 63,492 vested on each of November 20, 2024 and November 20, 2025, and 63,492 vesting on each of November 20, 2026 and November 20, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 28,229 | $24.78 | $699,523.09 |
DisclosureSEC source: 0001193125-25-293655 · ownership.xml · nonDerivative · entry 2 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,647 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 63,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-293655 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 30,000 | $25.11 | $753,321.00 |
DisclosureSEC source: 0001193125-25-286134 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,384 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,147 | $15.91 | $34,165.64 |
DisclosureSEC source: 0000950170-25-034687 · ownership.xml · nonDerivative · entry 3 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,384 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 71,278 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035537 · ownership.xml · derivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,278 Underlying: Ordinary Shares · 71,278 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,819 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,819 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034687 · ownership.xml · derivative · entry 4 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,384 Underlying: Ordinary Shares · 20,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 4,034 | $15.73 | $63,473.38 |
DisclosureSEC source: 0000950170-25-034687 · ownership.xml · nonDerivative · entry 2 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,531 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034687 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 63,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-129709 · ownership.xml · derivative · entry 3 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,476 Underlying: Ordinary Shares · 63,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on November 20, 2023, with 63,492 vested on November 20, 2024, and 63,492 vesting on each of November 20, 2025, November 20, 2026 and November 20, 2027. F5 · derivative.expiration_date: Restricted share units were granted on November 20, 2023, with 63,492 vested on November 20, 2024, and 63,492 vesting on each of November 20, 2025, November 20, 2026 and November 20, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 19,388 | $16.87 | $327,085.25 |
DisclosureSEC source: 0000950170-24-129709 · ownership.xml · nonDerivative · entry 2 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,104 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 63,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-129709 · ownership.xml · nonDerivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 81,845 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026063 · ownership.xml · derivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,845 Underlying: Ordinary Shares · 81,845 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 12:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 253,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056412 · doc4.xml · derivative · entry 1 Fox Christine · CIK 0001998173 · EVP, Head of U.S. Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,968 Underlying: Ordinary Shares · 253,968 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on November 20, 2023, with 63,492 vesting on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027. F2 · derivative.expiration_date: Restricted share units were granted on November 20, 2023, with 63,492 vesting on each of November 20, 2024, November 20, 2025, November 20, 2026 and November 20, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.